<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04766229</url>
  </required_header>
  <id_info>
    <org_study_id>RS21-002</org_study_id>
    <nct_id>NCT04766229</nct_id>
  </id_info>
  <brief_title>The Menopause After Cancer Study</brief_title>
  <acronym>MACS</acronym>
  <official_title>A Multimodal Technology-assisted Intervention for the Management of Menopause After Cancer: The Menopause After Cancer Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College Dublin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Irish Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Big Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College Dublin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will recruit women with vasomotor symptoms of menopause and a prior cancer&#xD;
      diagnosis, for whom conventional menopausal hormone therapy (MHT) is contraindicated for any&#xD;
      reason. This study will examine if the addition of psycho-social support and digital&#xD;
      cognitive behavioral therapy (CBT) for insomnia to standard non-hormonal pharmacotherapy can&#xD;
      improve quality of life for these women.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who are eligible and provide informed consent will be enrolled into this single arm&#xD;
      study. Patients will be prescribed non-hormonal pharmacotherapy tailored to the timing of&#xD;
      their predominant symptoms. They will be given access to an evidence based platform for&#xD;
      digital CBT for insomnia and asked to identify a partner or other companion who will commit&#xD;
      to providing psychosocial support to the research participant throughout the study period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 21, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global Quality of Life scores as measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ C30) instrument</measure>
    <time_frame>6 months</time_frame>
    <description>Global quality of life will be assessed using the EORTC QLQ C30 questionnaire. This is a 30 item questionnaire which has been extensively validated internationally and is specific to patients treated for cancer. Minimum global quality of life score is 0 with a maximum of 100 with a higher score representing a better quality of life.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bother/Interference of vasomotor symptoms of menopause as measured by the Hot Flush Rating Scale</measure>
    <time_frame>6 months</time_frame>
    <description>This will be measured by the Hot Flush Rating Scale which measures both frequency and impact of vasomotor symptoms. For this scale the minimum score is 1 and maximum score is 10 with higher scores indicating a greater degree of bother/interference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep dysfunction as measured by the Sleep Condition Indicator</measure>
    <time_frame>6 months</time_frame>
    <description>This will be measured using the Sleep Condition Indicator tool. Minimum score is 0 with maximum score of 32 with higher scores indicating better sleep.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Communication between participants and support person as measured by the Couples' Illness Communication Score.</measure>
    <time_frame>6 months</time_frame>
    <description>Will be measured quantitatively using Couples' Illness Communication Score. The minimum score of 8 and a maximum score of 40 with higher scores indicating better communication.</description>
  </other_outcome>
  <other_outcome>
    <measure>The experience of participating in the couples communication aspect of the study</measure>
    <time_frame>6 months</time_frame>
    <description>This will be explored qualitatively using semi structured interviews</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">205</enrollment>
  <condition>Menopause</condition>
  <condition>Cancer</condition>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants in single arm study</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Citalopram +/- Gabapentin + Sleepio + support person</intervention_name>
    <description>All participants will receive citalopram and/or gabapentin to manage vasomotor symptoms of menopause and will get access to digital CBT for insomnia and be asked to identify a support person</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Females over 18 years of age at the time of recruitment and onboarding.&#xD;
&#xD;
          2. Vasomotor symptoms of menopause&#xD;
&#xD;
          3. Previous or current cancer diagnosis&#xD;
&#xD;
          4. Conventional menopausal hormone therapy contraindicated for any reason&#xD;
&#xD;
          5. Can speak and read English proficiently&#xD;
&#xD;
          6. Competent using the internet and has access to smartphone or similar device&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. ECOG performance status &gt;3&#xD;
&#xD;
          2. Use of study medications to manage menopausal symptoms in the preceding 6 months&#xD;
&#xD;
          3. Use of CBT for insomnia in the preceding 6 months&#xD;
&#xD;
          4. Any contraindication to study medications&#xD;
&#xD;
          5. No internet access or competency issue with internet use&#xD;
&#xD;
          6. Unable to complete questionnaires or give informed consent&#xD;
&#xD;
          7. Current major mental illness&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donal Brennan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCD Dublin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fionan Donohoe, MB</last_name>
    <phone>+35317164497</phone>
    <email>fionan.donohoe@ucd.ie</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mater Misericordiae University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fionan Donohoe, MB</last_name>
      <phone>+35317164497</phone>
      <email>fionan.donohoe@ucd.ie</email>
    </contact>
    <investigator>
      <last_name>Donal Brennan, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cathy Kelly, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fionan Donohoe, MB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fionan Donohoe, MB</last_name>
      <phone>+35317164497</phone>
      <email>fionan.donohoe@ucd.ie</email>
    </contact>
    <investigator>
      <last_name>Donal Brennan, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Janice Walshe, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fionan Donohoe, MB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 17, 2021</study_first_submitted>
  <study_first_submitted_qc>February 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2021</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University College Dublin</investigator_affiliation>
    <investigator_full_name>Donal Brennan</investigator_full_name>
    <investigator_title>Professor of Gynaecological Oncology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We do not plan to share IPD with other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

